Multiple Sclerosis Therapeutics Market, by Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents and Others), by Route of Administration (Oral and Injection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region - Global Trends, and Forecast till 2025

  • Published On : Feb 2018 |
  • Pages : 148 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Multiple Sclerosis Therapeutics Market – Offering Long-term Disease Management

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. The disease leads in malfunction of the nervous system to communicate, which in turn causes several signs and symptoms, including physical, mental, and psychiatric problems. Double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination are some of the other symptoms. The types of MS include relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). RPMS is the most common type characterized by defined attacks with increasing neurological symptoms, PPMS is the rare form characterized by gradual progression of disease, whereas SPMS is commonly identified in people living with relapsed-remitting MS. The most common symptoms of the disease include partial or complete vision loss, prolonged vision loss, lack of coordination, and slurred speech.

A combination of genetic and environmental factors is responsible for the occurrence of the condition. According to a study by International Progressive Alliance, 2013, MS is two to three times more common in women than in men, suggesting that hormones play a significant role in determining susceptibility to the disease.

The global multiple sclerosis therapeutics market was valued at US$ 19.6 billion in 2016 and is expected to witness a robust CAGR of 2.5% over the forecast period (2017 - 2025).

Figure 1. Global Multiple Sclerosis Therapeutics Market (US$ Mn), by Region, 2016

multiple sclerosis therapeutics market

Source: Coherent Market Insights (2018)

Increasing prevalence of multiple sclerosis to augment market growth

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000 population. North America dominates the multiple sclerosis therapeutics market owing to the high prevalence of the condition and the rising economic burden of the disease leading to the adoption of novel therapeutics. According to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Higher therapy cost is restraining the growth of the multiple sclerosis therapeutics market.

Intensive R&D programs undertaken by organizations to accelerate the market growth     

Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, contributing to be a vital factor driving the growth of global multiple sclerosis therapeutics market. For instance, the scientists at Multiple Sclerosis International Federation are undertaking research to understand, manage and treat the disease and are currently undertaking clinical trials to investigate the potential of stem cell therapies including mesenchymal stem cell (MSCs), hematopoietic stem cells (HSCs) and neural stem cells (NSCs). Also, in 2013, the Progressive MS Alliance was established to specifically research and develop more treatment options for people with the progressive forms of MS which currently has a total of 20 projects with researchers based in nine countries. Additionally, in 2015, the MS Society of Canada and the Canadian Institute of Health Research funded a new research to the University of Alberta to examine novel therapeutic strategy to reduce inflammation in the brain, a key factor contributing to the muscle disability associated with multiple sclerosis.

The major players operating in the global multiple sclerosis therapeutics market include Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.

The multiple sclerosis therapeutic agents are intended to promote neurorepair and neuroprotection to prevent disease progression. The disease modifying therapeutics are currently under clinical development to specifically target the disease while avoiding frequent therapeutic administrations. A variety of corticosteroids, immunosuppressants and monoclonal antibodies are approved and recommended to reduce inflammation in multiple sclerosis. The complex nature of disease with its unique individual patient course renders variable clinical outcomes in different patients. Although there is no cure for multiple sclerosis, the currently available therapeutics modify the disease course, accelerate recovery from attacks, and help in managing symptoms.

Market Dynamics

The major factors driving growth of the multiple sclerosis therapeutics market include rise in research and development ultimately leading to the launch of novel drug candidates and the rising prevalence of the condition in children. For instance, in 2014, Plegridy (peginterferon beta-1a) manufactured by Biogen, a disease modifying therapy was approved for the long-term treatment of relapsing forms of multiple sclerosis. According to Multiple Sclerosis Society, approximately five to ten per cent of people with MS experienced their first symptoms before the age of 16. However, the inability of drugs to prevent disease progression and disability, side effects of the approved drugs such as increased risk of infections, flu-like symptoms and progressive multifocal leukoencephalopathy (PML), a viral disease of the brain are the factors hindering market growth.

Key features of the study:

  • This report provides in-depth analysis of multiple sclerosis therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global multiple sclerosis therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Novartis AG, Teva Pharmaceuticals Industries Ltd., Sanofi Genzyme, Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, market expansion, and marketing tactics
  • The global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the multiple sclerosis therapeutics market

Detailed Segmentation:

  • Global Multiple Sclerosis Therapeutics Market, By Drug Class:
    • Beta Interferon
    • Corticosteroids
    • Monoclonal Antibodies
    • Antineoplastic Agents
    • Others
  • Global Multiple Sclerosis Therapeutics Market, By Route of Administration:
    • Oral
    • Injection
  • Global Multiple Sclerosis Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • E-Commerce
  • Global Multiple Sclerosis Therapeutics Market, By Geography:
    • North America
      • By Drug Class:
        • Beta Interferon
        • Corticosteroids
        • Monoclonal Antibodies
        • Antineoplastic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Beta Interferon
        • Corticosteroids
        • Monoclonal Antibodies
        • Antineoplastic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Beta Interferon
        • Corticosteroids
        • Monoclonal Antibodies
        • Antineoplastic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Beta Interferon
        • Corticosteroids
        • Monoclonal Antibodies
        • Antineoplastic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Beta Interferon
        • Corticosteroids
        • Monoclonal Antibodies
        • Antineoplastic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Beta Interferon
        • Corticosteroids
        • Monoclonal Antibodies
        • Antineoplastic Agents
        • Others
      • By Route of Administration:
        • Oral
        • Injection
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • E-Commerce
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Novartis AG*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Teva Pharmaceuticals Industries Ltd.
    • Sanofi S.A.
    • Bayer AG
    • Pfizer, Inc.
    • Biogen Idec
    • Merck & Co., Inc.
    • AbbVie, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • Regulatory Scenario
    • Reimbursement Scenario
    • Alternative Therapies
    • Pipeline Analysis
    • Supply Chain Analysis
    • PEST Analysis
    • Epidemiology
  4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Beta Interferon
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Corticosteroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Monoclonal Antibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Antineoplastic Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Injection
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, 2017 – 2025
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
    • E-Commerce
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
  7. Global Multiple Sclerosis Therapeutics Market, By Region, 2017 – 2025, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2016 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 – 2025
    • North America
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • Brazil
        • Mexico
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
      • Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis (3x3 Matrix)
    • Company Profiles
      • Novartis AG*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Teva Pharmaceuticals Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Bayer AG
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Biogen Idec
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • AbbVie, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 40 figures on "Multiple Sclerosis Therapeutics Market - Global forecast to 2025”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.